IVRO (Invitro International) Other Long-Term Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invitro International Other Long-Term Liabilities?

Invitro International IVRO +1.33% Other Long-Term Liabilities is $0.00 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Invitro International's other long-term liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Invitro International's quarterly other long-term liabilities increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) but then declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Invitro International's annual other long-term liabilities increased from Sep. 2096 ($-0.10 Mil) to Sep. 2024 ($0.00 Mil) but then declined from Sep. 2024 ($0.00 Mil) to Sep. 2025 ($-0.00 Mil).

Invitro International Other Long-Term Liabilities Related Terms

Invitro International Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Invitro International's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invitro International Other Long-Term Liabilities Chart

Invitro International Annual Data
Trend Feb90 Feb91 Sep92 Sep93 Sep94 Sep95 Sep96 Sep24 Sep25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 -0.10 0.00 -0.00

Invitro International Quarterly Data
Sep94 Dec94 Mar95 Jun95 Sep95 Dec95 Mar96 Jun96 Sep96 Dec96 Mar97 Jun97 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Invitro International Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
Invitro International (IVRO) has a Other Long-Term Liabilities of $0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Invitro International and its competitors.
Is Invitro International's Other Long-Term Liabilities too high?
Invitro International's current Other Long-Term Liabilities is $0.00 Mil.
How does Invitro International's Other Long-Term Liabilities compare to IDTA and PRPH?
Invitro International's Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Invitro International and its competitors. Invitro International's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Other Long-Term Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Invitro International (IVRO), the current Other Long-Term Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invitro International Business Description

Address 330 East Orangethorpe Avenue, Suite D, Placentia, CA, USA, 92870
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.